Electrical Endoscopic Mass Characterizer (EEMC)

Description

Innovative Endoscopic Cancer Detection Device for Early GI Diagnosis

The Electrical Endoscopic Mass Characterizer (EEMC) is an innovative endoscopic cancer detection device developed to address one of the biggest challenges in oncology: the early detection of gastrointestinal (GI) cancers such as esophageal, gastric, and pancreatic malignancies.

Most GI cancers are diagnosed at advanced stages, often due to the limitations of standard endoscopic evaluations. EEMC changes that. It empowers clinicians to detect high-risk lesions in real time, during routine endoscopic procedures, using advanced electrical impedance spectroscopy (EIS).

What Makes EEMC Different?

EEMC is a non-invasive, real-time diagnostic probe integrated into modified endoscopic biopsy forceps. During a standard upper GI endoscopy, the endoscopist typically decides—based on visual cues and experience—whether or not to take a biopsy.

EEMC eliminates this uncertainty.

By analyzing impedance magnitude and phase, it identifies excision-worthy lesions that may otherwise go unnoticed. The result?
✅ Reduced misdiagnoses
✅ Minimized unnecessary biopsies
✅ Lower patient costs
✅ Earlier cancer detection

Clinical Performance and Accuracy

In a clinical study involving 52 patients, EEMC demonstrated exceptional diagnostic performance:

Sensitivity: 94.7%
Specificity: 93.9%
Accuracy: 94.2%
Time per diagnosis: Less than 10 seconds

This data confirms EEMC’s role as a next-generation GI biopsy tool for early and accurate tumor identification.

Advantages of the Electrical Endoscopic Mass Characterizer

Real-time, intraoperative diagnosis during upper GI endoscopy
Non-invasive detection of small or hidden lesions
Enhanced endoscopic decision-making
Reduces missed early-stage cancers
Seamlessly integrates into standard clinical workflow
Backed by research, international development, and patents

EEMC is especially effective for identifying small polyps and early-stage lesions that may be overlooked during conventional endoscopic procedures.

Hospitech Cancer Care: Pioneering Oncology Innovation

The EEMC device is developed by Hospitech Cancer Care Innovations, a leader in oncology diagnostic technology. The company’s portfolio also includes:

Cancer Diagnostic Probe (CDP)
Impedimetric Tumor Detection System (ITDS)
ElectroChemoTherapy (ECT)
Gamma Probe for intraoperative localization

Hospitech’s technologies are backed by international collaborations, peer-reviewed publications, and granted U.S. patents — making it a trusted partner for early cancer detection.

Designed for Global Clinical Use

Whether you’re a gastroenterologist, oncology surgeon, clinical researcher, or distributor, EEMC provides a powerful diagnostic advantage. Its fast, accurate, and cost-effective performance enables better patient care and opens new possibilities in cancer screening and surveillance worldwide.

Advance GI Diagnostics with EEMC

Hospitech invites healthcare professionals, research institutions, and medical technology investors to explore the global potential of the Electrical Endoscopic Mass Characterizer.

Bring precision oncology to the GI suite with this breakthrough technology in real-time endoscopic cancer detection.

TECHNOLOGY

Technology of Electrical Endoscopic Mass Characterizer

EEMC analysis is based on Electrical Impedance Spectroscopy (EIS) that is an increasingly promising technique with immense potential in detecting and characterizing various diseases, with a particular focus on cancer to differentiate normal from premalignant and malignant tissues. The responses are precisely correlated to tissue dielectric properties due to their pathophysiological changes during cancer, including increasing cell size, cell membrane permeability, changes in water content within the cell, etc. The results of this device evaluate the changes in the dielectric properties of cells as a result of their pathophysiological changes during cancerous growth, including the increase in cell size, the permeability of the cell membrane changes in the water content inside the cell, etc.

FEATURES

Features of Electrical Endoscopic Mass Characterizer

Determining the masses of the gastrointestinal tract that require sampling and Excision
Assisting in detecting cancer in the early stages.
Reducing pathology costs if the tissue if the tissue doesn’t require further investigation
Assisting the patient to examine all suspicious tissues.
Increasing the accuracy of sampling in large masses by determining the most pathological part of the mass
94% diagnostic accuracy in a clinical trial with 60 tumors mass

ACHIEVEMENT

Articles

National Library of Medicine

Digestive Diseases and Sciences

patents

US20220022771A1

CLINIAL TRIAL RESULTS

Studies have shown that this technique has high sensitivity and specificity in detecting small polyps and lesions that may not be visible during traditional endoscopy. Overall, results of EEMC indicate its potential in cancer screening and surveillance.

Sensitivity: 93%
Specificity: 89%
Accuracy: 90%

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Electrical Endoscopic Mass Characterizer (EEMC)”

1. What is the Electrical Endoscopic Mass Characterizer (EEMC)?

EEMC is a real-time, high-precision cancer detection device that uses Electrical Impedance Spectroscopy (EIS) to detect and characterize masses in the gastrointestinal tract during endoscopy.

2. What is the purpose of EEMC?

EEMC is designed to discriminate high-risk excision-required lesions during endoscopy, enabling early detection and precise characterization of gastrointestinal cancer.

3. How does EEMC work?

EEMC analysis is based on the changes in dielectric properties of cells during cancerous growth, including changes in cell size, membrane permeability, and water content.

4. What are the benefits of using EEMC?

EEMC can assist in detecting cancer in the early stages, reducing pathology costs, and increasing the accuracy of sampling in large masses.

5. How accurate is EEMC?

EEMC has a diagnostic accuracy of 94% in a clinical trial with 60 tumors.

6. Can EEMC detect small polyps and lesions that may not be visible during traditional endoscopy?

Yes, studies have shown that EEMC has high sensitivity and specificity in detecting small polyps and lesions that may not be visible during traditional endoscopy.

7. Is EEMC suitable for cancer screening and surveillance?

Yes, results of EEMC indicate its potential in cancer screening and surveillance.

8. Can EEMC reduce the need for unnecessary biopsies?

Yes, EEMC can help reduce the need for unnecessary biopsies by providing real-time information on the most pathological parts of a mass, allowing for more targeted sampling.